Target Name: DUOXA1
NCBI ID: G90527
Review Report on DUOXA1 Target / Biomarker Content of Review Report on DUOXA1 Target / Biomarker
DUOXA1
Other Name(s): dual oxidase maturation factor 1 delta | DUOXA1 variant 1 | FLJ32334 | NIP | DOXA1_HUMAN | Numb-interacting protein | Dual oxidase maturation factor 1 beta | Dual oxidase activator 1 | mol | Dual oxidase maturation factor 1 delta | homolog of Drosophila Numb-interacting protein | Mol | dual oxidase maturation factor 1 beta | Dual oxidase maturation factor 1 | dual oxidase activator 1 | Dual oxidase maturation factor 1, transcript variant 1 | Dual oxidase maturation factor 1 gamma | Dual oxidase maturation factor 1 (isoform 1) | dual oxidase maturation factor 1 gamma | dual oxidase maturation factor 1 alpha | dual oxidase maturation factor 1 | NUMBIP | Dual oxidase maturation factor 1 alpha | Homolog of Drosophila Numb-interacting protein

DUOXA1: A Protein Linked To Cell Death and Survival

Dual oxidase maturation factor 1 (DUOXA1) is a protein that plays a crucial role in the regulation of cell death and survival. Mutations in the DUOXA1 gene have been linked to a range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Despite the significant impact of DUOXA1 mutations on human health, the precise mechanisms underlying its function and dysfunction are not well understood.

In this article, we will explore the biology and implications of DUOXA1, with a focus on its potential as a drug target or biomarker. We will discuss the current state of research on DUOXA1 mutations, and the potential clinical applications of targeting this protein.

The biology of DUOXA1

DUOXA1 is a member of the superfamily of proteins known as the maturation factors. These proteins are involved in the regulation of cellular processes that ensure cell survival and integrity, including the regulation of cell death and the response to environmental stressors.

The DUOXA1 protein is a 21-kDa protein that is expressed in a variety of tissues, including brain, heart, and muscle. It is composed of two distinct domains: an N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal domain is responsible for the protein's localization to the endoplasmic reticulum, while the C-terminal domain is involved in the regulation of its stability and activity.

DUOXA1 functions as a negative regulator of cell survival. It has been shown to promote the oxidation of cellular lipids, which is a hallmark of cell death. This oxidation generates reactive oxygen species (ROS) that can damage cellular components and contribute to the development of oxidative stress-induced diseases. By promoting cell death through ROS-mediated damage, DUOXA1 may be a potential drug target or biomarker for a variety of diseases.

The implications of DUOXA1 mutations

Mutations in the DUOXA1 gene have been linked to a range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. These mutations can alter the structure and function of the protein, leading to changes in its regulation of cellular processes.

Studies have shown that DUOXA1 mutations can alter the expression and stability of the protein. For example, research has shown that mutations in the DUOXA1 gene can lead to the production of unstable forms of the protein that are less stable and less effective in regulating cell death. These mutations may also alter the protein's interactions with other cellular components, leading to changes in its function.

The potential clinical applications of DUOXA1 targeting

DUOXA1 mutations have been linked to a range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Targeting this protein as a drug or biomarker may have significant implications for the treatment of these diseases.

One potential approach to targeting DUOXA1 is through the inhibition of its activity. This can be achieved through a variety of methods, including the use of small molecules, antibodies, or genetic modifiers. By inhibiting the activity of DUOXA1, researchers may be able to reduce the formation of ROS and protect against the development of oxidative stress-induced diseases.

Another potential approach to targeting DUOXA1 is through the use of biomarkers. By identifying individuals with DUOXA1 mutations, researchers may be able to develop diagnostic tools and therapies based on these mutations. This could include the use of genetic tests, protein arrays, or other biomarkers that are specific for DUOXA1 mutations.

Conclusion

DUOXA1 is a protein that plays a crucial role in the regulation of cell death and survival. Mutations in the DUOXA1 gene have been linked to a range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. The potential clinical applications of targeting this protein as a drug or biomarker are significant, and research is ongoing to determine its full potential

Protein Name: Dual Oxidase Maturation Factor 1

Functions: May be required for the maturation and the transport from the endoplasmic reticulum to the plasma membrane of functional DUOX1

The "DUOXA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUOXA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

DUOXA2 | DUS1L | DUS2 | DUS3L | DUS4L | DUSP1 | DUSP10 | DUSP11 | DUSP12 | DUSP13 | DUSP14 | DUSP15 | DUSP16 | DUSP18 | DUSP19 | DUSP2 | DUSP21 | DUSP22 | DUSP23 | DUSP26 | DUSP28 | DUSP29 | DUSP3 | DUSP4 | DUSP5 | DUSP5P1 | DUSP6 | DUSP7 | DUSP8 | DUSP8P5 | DUSP9 | DUT | DUTP6 | DUX1 | DUX3 | DUX4 | DUX4L1 | DUX4L13 | DUX4L16 | DUX4L18 | DUX4L19 | DUX4L2 | DUX4L20 | DUX4L23 | DUX4L3 | DUX4L37 | DUX4L4 | DUX4L5 | DUX4L6 | DUX4L7 | DUX4L8 | DUX4L9 | DUXA | DUXAP10 | DUXAP3 | DUXAP8 | DUXAP9 | DVL1 | DVL2 | DVL3 | DXO | DYDC1 | DYDC2 | DYM | Dynactin | DYNAP | DYNC1H1 | DYNC1I1 | DYNC1I2 | DYNC1LI1 | DYNC1LI2 | DYNC2H1 | DYNC2I1 | DYNC2I2 | DYNC2LI1 | DYNLL1 | DYNLL2 | DYNLRB1 | DYNLRB2 | DYNLRB2-AS1 | DYNLT1 | DYNLT2 | DYNLT2B | DYNLT3 | DYNLT4 | DYNLT5 | DYRK1A | DYRK1B | DYRK2 | DYRK3 | DYRK4 | DYSF | Dystrophin-Associated Glycoprotein Complex | DYTN | DZANK1 | DZIP1 | DZIP1L | DZIP3 | E2F Transcription Factor | E2F-6 complex